Skip to main content

Table 2 Treatment details for 9 patients with esthesioneuroblastoma

From: Esthesioneuroblastoma in pediatric and adolescent age. A report from the TREP project in cooperation with the Italian Neuroblastoma and Soft Tissue Sarcoma Committees

Pt. Protocol type Initial
CT (No. of cycles) Response to CT Delayed
Outcome (years after diagnosis) Long-term sequelae
1 RMS Macroscopic residuals VAdIA (9) PR No No DOD (0.7) -
2 RMS Biopsy VAdIA (12) CR No Yes
(53 Gy)
NED (11.5) GH deficit, hypogonadism, hypothyroidism, chronic sinusitis, hypovision and cataract, hearing loss, dental abnormalities, facial bones hypoplasia
3 RMS Biopsy VAdIA + Carbo/E (5) PR Microscopic residuals Yes
(50 Gy)
NED (13) Palate deformity
4 RMS Biopsy VAdIA (12) MR Complete resection Yes
(60 Gy)
NED (14) Hypothyroidism, xerostomia, oligospermia
5 RMS Microscopic residuals VAdIA (9) NE No Yes*
(42 Gy)
NED (9.2) Chronic headache, hypothyroidism, attention-deficit/hyperactivity disorder
6 NBL Macroscopic residuals VAdC + CDDP/E (6) SD Microscopic residuals Yes
(48 Gy)
NED (11.1) loss of sense of smell, facial bone hypoplasia, recurrent keratoconjunctivitis, maculopathy
7 NBL Biopsy VAdCA + CDDP/E+
i.t. MTX (15)
PR No Yes
(60 Gy)
NED (23) Amaurosis, hypothyroidism, GH deficiency, xerostomia, facial bones hypoplasia
8 NBL Lymph node biopsy VAdC/CDDP (7) CR No Yes
(47 Gy)
NED (20.2) Peripheral neuropathy
9 RMS Macroscopic residuals VAdC (12) NE No Yes
(60 Gy)
NED (17.1) Chronic sinusitis
  1. Pt: patient; CT: chemotherapy; RT: radiotherapy; RMS: rhabdomyosarcoma; V: vincristine, Ad:adriamycin, I: ifosfamide, A actinomycin-D; PR: partial response; DOD: dead of disease; CR: complete response; Gy: grays; NED: not evidence of disease; GH: growth hormone; Carbo: carboplatin; E: etoposide; PR: partial response; MR: minor response; NE: not evaluable; NBL: neuroblastoma; C: cyclophosphamide; CDDP: cisplatin; SD: stable disease; i.t. MTX: intrathecal methotrexate